Register and share your invite link to earn from video plays and referrals.

Search results for HotStocks
HotStocks community
One keyword maps to one global community path.
Create community
People
Not Found
Tweets including HotStocks
Trading Hot Stocks with Ripster Clouds | $BE, $MRNA, $MU & $SNDK Watch the video to learn how Ripster Clouds help identify momentum and manage hot stock setups 🎯 @ripster47 | @tenet_research | @TenetCharts
Show more
💡 Best Strategy to Invest in Hot Stocks: POST EARNING LONG > Find hottest stocks with tenetresearch > EPS/REV growing > Strong Chart into Earnings > Buy Dips vs Technical Level & Clouds Examples: $BE $DELL Exact Entries, Risk & Returns Explained Which one are you Buying?
Show more
🚨 Breaking Alert NVIDIA ($NVDA) CEO Jensen Huang just said on CNBC live: “Investing in SpaceX, Anthropic, and OpenAI is like buying $AMZN, $GOOGL, or $MU in their early days.” As the leader of the world’s most valuable company — now valued at $5.43 trillion — his perspective carries substantial industry insight and credibility. I believe these three opportunities in the second half of this year could potentially double your capital and accelerate your path to becoming a millionaire. Here are the beginner‑essential rules I’ve distilled through years of trial and error. (Save these.) If you can’t follow them, don’t buy stocks. Down 6% → Sell everything immediately (stop‑loss) Up more than 20% → Take profit on half (let the rest run) IPO day or hype‑driven news surge → Don’t chase Only deploy a small, pre‑planned amount and stay patient. Emotional FOMO → Absolutely forbidden Ignore any impulse that pushes you outside your rules. If you can’t stick to discipline, don’t enter the market. Hot stocks can skyrocket in seconds — and crash just as fast. Save these rules. Stay sharp. Stay disciplined.
Show more
China Life delivered a textbook example of institutional portfolio rebalancing this July, offering vital lessons for retail investors navigating volatile equity markets. On July 8, eight asset management plans managed by China Life offloaded all their holdings in GigaDevice, a leading Chinese memory chip firm. In total, around 1.1 million shares were sold at prices ranging from 611 yuan to 624 yuan, locking in roughly 680 million yuan in profits. The timing proved impeccable. GigaDevice hit an all-time high of 843 yuan on July 1 and had already tumbled nearly 30% by July 8. At first glance, many market participants thought the insurer sold too late from the absolute peak. Hindsight paints a different picture: by July 20, the stock slumped to 432 yuan, more than halving from its record high. China Life essentially exited near the summit of the rally. One striking detail stands out. None of these eight asset portfolios featured among GigaDevice’s top ten tradable shareholders in the first-quarter report. The massive positions remained hidden from public view until the sell-off. For a large institutional investor to quietly accumulate such a sizable stake and exit decisively while market liquidity remained sufficient demonstrates sharp market judgment. The strategy grows even more intriguing when paired with parallel moves inside the group. On the exact same day China Life dumped its memory chip exposure, China Life Asset Management, its primary investment arm, made net purchases of equity assets exceeding 10 billion yuan in a single session. In short, the insurer booked massive gains on overheated tech stocks while deploying heavy capital into new, undervalued segments. Publicly, China Life issued statements voicing firm confidence in China’s long-term economic prospects and capital market outlook. Investors should carefully interpret the gap between its upbeat rhetoric and tactical trading actions. This dual operation boils down to one core strategy: dynamic portfolio rebalancing. Institutional investors trim positions that have surged to stretched valuations and build exposure to sectors that have undergone meaningful corrections. Retail investors frequently struggle with this discipline. Most ordinary traders become emotionally anchored to hot stocks, unwilling to take profits when prices reach excessive levels, and hesitate to buy quality assets amid market pullbacks. The contrast between words and actions highlights a timeless investing truth. Confidence in the long-term prospects of an economy or market does not mean blindly holding overvalued stocks through every cycle. Market cycles create constant valuation rotation. Smart capital harvests gains from inflated assets and recycles proceeds into overlooked opportunities trading at cheaper valuations. China Life’s trade is a masterclass for individual investors. Do not fall in love with individual stocks. When valuations detach from fundamentals and speculative sentiment dominates, lock in profits without hesitation. Maintain capital flexibility to seize opportunities when market sentiment turns pessimistic. Mastering this rotation between expensive and cheap assets separates consistent long-term winners from passive buy-and-hold investors trapped in market crashes.
Show more
🔥 Did you catch today’s IPO wave on BiFinance? 白鴿在線 soared up to +260.20%, while 禮邦醫藥 and 海光芯正 also posted strong gains of +98.14% and +61.93%. Quality IPOs. Strong market momentum. Real opportunities. Stay tuned for more new listings on BiFinance. 🚀 #BiFinance# #IPO# #HKStocks# #Trading#
Show more
🚀 New Listing Alert #BiFinance# has officially launched Liuliumei/HKD! Liuliumei is a leading enterprise in China's fruit snack industry and a pioneer in plum products, committed to bringing consumers natural, healthy, and innovative snack experiences. 📈 Trading Pair: Liuliumei/HKD ⏰ Trading Started: June 18, 10:00 (UTC+8) Trade Hong Kong stocks and quality global assets on BiFinance. #Liuliumei# #HKStocks# #HongKongStocks# #BiFinance# #Trading#
Show more
🚀 BiFinance IPO Series | 天辰生物-B HK STOCK IPO 👉 As a biotechnology company focused on innovative drug development, 天辰生物-B is committed to creating globally best-in-class and first-in-class therapies for cancer and other serious diseases. 🧬 Biotech × HK Stock IPO 🌍 Bridging Traditional Finance and Web3 📈 IPO Price: 96.06 HKD ⏰ Subscription Starts: 2026/5/28 9:00 Innovation in biotechnology is accelerating toward global capital markets, reshaping the future of healthcare and finance. #BiFinance# #IPO# #HKStocks# #Biotech# #Web3#
Show more